Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts

Journal of Investigative Dermatology

Volumn 124, Issue 2, 2005, Pages 324-330

  Jinnin, Masatoshi ^a   Ihn, Hironobu ^a   Mimura, Yoshihiro ^a   Asano, Yoshihide ^a   Yamane, Kenichi ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Tissue inhibitor of metalloproteinases; Tissue remodeling; Transforming growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; PROCOLLAGEN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN EXPRESSION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST;

EID: 12944268865     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23601.x     Document Type: Article

References (45)

1. Apras S, Ertenli I, Ozbalkan Z, et al: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256-2261, 2003
2. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
3. Boros P, Miller CM: Hepatocyte growth factor: A multifunctional cytokine. Lancet 345:293-295, 1995
4. Brummer O, Bohmer G, Hollwitz B, Flemming P, Retry KU, Kuhnle H: MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study. Gynecol Oncol 84:222-227, 2002
5. Brunet CL, Sharpe PM, Ferguson MWJ: Inhibition of TGF-β3 (but not TGF-β1 or TGF-β2) activity prevents normal and mouse embryonic palate fusion. Int J Dev Biol 39:345-355, 1995
6. Falanga V, Greenberg AS, Ochoa SM, Roberts AB, Falabella A, Yamaguchi Y: Stimulation of collagen synthesis by anabolic steroid stanozol. J Invest Dermatol 111:1193-1197, 1998
7. Gohda E, Tsubouchi H, Nakayama H, et al: Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 81:414-419, 1988
8. Haustein UF: Systemic sclerosis-scleroderma. Dermatol Online J 8:3, 2002
9. Hitraya EG, Jimenez SA: Transcriptional activation of the α(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Arthritis Rheum 39:1347-1354, 1996
10. Hojo S, Fujita J, Yoshinouchi T, et al: Hepatocyte growth factor and neutrophil elastase in idiopathic pulmonary fibrosis. Respir Med 91:511-516, 1997
11. Holleran WM, Galardy RE, Gao WN, Levy D, Tang PC, Elias PM: Matrix metalloproteinase inhibitors reduce phorbol ester-induced cutaneous inflammation and hyperplasia. Arch Dermatol Res 289:138-144, 1997
12. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS: Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol 40:638-643, 2001
13. Ihn H, LeRoy EC, Trojanowska M: Oncostatin M stimulates transcription of the human α2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 272:24666-24672, 1997
14. Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M: Transcriptional regulation of the human α2(I) collagen gene. Combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem 271:26717-26723, 1996
15. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K: IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway. J Immunol 168:1895-1902, 2002
16. Ihn H, Yamane K, Kubo M, Tamaki K: Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor β receptors. Arthritis Rheum 44:474-480, 2001
17. Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J: Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis. Biochem J 237:837-843, 1986
18. Kawaguchi Y, Harigai M, Fukasawa C, Hara M: Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis. J Rheumatol 26:1012-1013, 1999
19. Kawaguchi Y, Harigai M, Hara M, et al: Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol 29:1877-1883, 2002
20. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M: Increased expression of TGF-β receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 110:47-51, 1998
21. Kikuchi K, Smith EA, LeRoy EC, Trojanowska M: Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts. Biochem Biophys Res Commun 187:45-50, 1992
22. Korn JH: Immunologic aspects of scleroderma. Curr Opin Rheumatol 1:479-484, 1989
23. Kuroda K, Shinkai H: Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 289:567-572, 1997
24. LeRoy EC: Increased collagen synthesis by scleroderma skin fibroblasts in vitro: A possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54:880-889, 1974
25. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-206, 1988
26. Matusuda Y, Matsumoto K, Ichida T, Nakamura T: Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal dysfunction in rats. J Biochem 118:643-649, 1995
27. Matsuda Y, Matsumoto K, Yamada A, et al: Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 26:81-89, 1997
28. Mauch C, Krieg T: Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am 16:93-107, 1990
29. Nakamura T, Nawa K, Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122:1450-1459, 1984
30. Nakamura T, Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-443, 1989
31. Ozaki I, Zhao G, Mizuta T, et al: Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 36:169-178, 2002
32. Pope JE, Bellamy N, Seibold JR, et al: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351-1358, 2001
33. Rutter JL, Benbow U, Coon CI, Brinckerhoff CE: Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1β (IL-1β) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem 66:322-336, 1997
34. Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239-242, 1987
35. Takada S, Namiki M, Takahara S, et al: Serum HGF levels in acute renal rejection after living related renal transplantation. Transpl Int 9:151-154, 1996
36. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y: Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 103:359-363, 1994
37. Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480-1488, 2003
38. Tsubouchi H, Kawakami S, Hirono S, et al: Prediction of outcome in fulminant hepatic failure by serum human hepatocyte growth factor. Lancet 340:307, 1992
39. Ueki T, Kaneda Y, Tsutsui H, et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230, 1999
40. Varga J: Scleroderma and Smads: Dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 46:1703-1713, 2002
41. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, Bakker AH: Modified proenzymes as artificial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 323:603-609, 1997
42. Weidner KM, Arakaki N, Hartmann G, et al: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88:7001-7005, 1991
43. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K: Antagonistic effects of TNF-alpha on TGF-β signaling through down-regulation of TGF-β receptor type II in human dermal fibroblasts. J Immunol 171:3855-3862, 2003
44. Yasuda H, Imai E, Shiota A, Fujise N, Morinaga T, Higashio K: Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 24:636-642, 1996
45. Zarnegar R, Michalopoulos G: Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res 49:3314-3320, 1989